Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19
| Autor: | Molly J. Destro Borgen, Sidna M. Tulledge-Scheitel, Alexander Heyliger, Caroline G. Wilker, Richard F. Arndt, Colin Pawlowski, Andrew D. Badley, Dennis M. Bierle, Sara N. Hanson, Leigh L. Speicher, John C. O’Horo, AJ Venkatakrishnan, Raymund R. Razonable, Lori L Arndt, Robert Orenstein, Jennifer J. Larsen, Patrick Lenehan, Arjun Puranik, Ravindra Ganesh, Sarah J. Bell |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Lightheadedness Nausea Population Antibodies Monoclonal Humanized Article Disease-Free Survival law.invention law Risk Factors Internal medicine Medicine Humans Adverse effect education Aged education.field_of_study business.industry SARS-CoV-2 COVID-19 Odds ratio Middle Aged Intensive care unit COVID-19 Drug Treatment Hospitalization Survival Rate Intensive Care Units Cohort Administration Intravenous Female Clinical Medicine medicine.symptom business Body mass index |
| Zdroj: | medRxiv J Clin Invest |
| Popis: | BackgroundClinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed.Methods2,335 patients who received single-dose bamlanivimab infusion between November 12, 2020 to February 17, 2021 were compared with a propensity-matched control of 2,335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states. The primary outcome was the rate of hospitalization at days 14, 21 and 28.ResultsThe median age of the population was 63; 47.3% of the bamlanivimab-treated cohort were ≥65 years; 49.3% were female. High-risk characteristics included hypertension (54.2%), body mass index ≥35 (32.4%), diabetes mellitus (26.5%), chronic lung disease (25.1%), malignancy (16.6%), and renal disease (14.5%). Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs 3.5%; Odds Ratio [OR], 0.38), 21 (1.9% vs 3.9%; OR, 0.46), and 28 (2.5% vs 3.9%; OR, 0.61). Secondary exploratory outcomes included lower intensive care unit admission rates at days 14 (0.14% vs 1%; OR, 0.12), 21 (0.25% vs 1%; OR: 0.24) and 28 (0.56% vs 1.1%; OR: 0.52), and lower all-cause mortality at days 14 (0% vs 0.33%), 21 (0.05% vs 0.4%; OR,0.08) and 28 (0.11% vs 0.44%; OR, 0.01). Adverse events were uncommon with bamlanivimab, occurring in 19/2355, most commonly fever (n=6), nausea (n=5), and lightheadedness (n=3).ConclusionsAmong high-risk patients with mild to moderate COVID-19, treatment with bamlanivimab was associated with a statistically significant lower rate of hospitalization compared with usual care.FundingMayo Clinic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|